<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>5(2)</volume><submitter>Gregory MH</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Invasive fungal infections are a devastating complication of inflammatory bowel disease (IBD) treatment. We aimed to determine the incidence of fungal infections in IBD patients and examine the risk with tumor necrosis factor-alpha inhibitors (anti-TNF) compared with corticosteroids.&lt;h4>Methods&lt;/h4>In a retrospective cohort study using the IBM MarketScan Commercial Database we identified US patients with IBD and at least 6 months enrollment from 2006 to 2018. The primary outcome was a composite of invasive fungal infections, identified by ICD-9/10-CM codes plus antifungal treatment. Tuberculosis (TB) infections were a secondary outcome, with infections presented as cases/100 000 person-years (PY). A proportional hazards model was used to determine the association of IBD </pubmed_abstract><journal>Crohn's &amp; colitis 360</journal><pagination>otad010</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9999356</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Corticosteroids Increase the Risk of Invasive Fungal Infections More Than Tumor Necrosis Factor-Alpha Inhibitors in Patients With Inflammatory Bowel Disease.</pubmed_title><pmcid>PMC9999356</pmcid><pubmed_authors>Deepak P</pubmed_authors><pubmed_authors>Stwalley D</pubmed_authors><pubmed_authors>Mejia-Chew C</pubmed_authors><pubmed_authors>Spec A</pubmed_authors><pubmed_authors>Gremida A</pubmed_authors><pubmed_authors>Nickel KB</pubmed_authors><pubmed_authors>Olsen MA</pubmed_authors><pubmed_authors>Gregory MH</pubmed_authors><pubmed_authors>Ciorba MA</pubmed_authors><pubmed_authors>Rood RP</pubmed_authors></additional><is_claimable>false</is_claimable><name>Corticosteroids Increase the Risk of Invasive Fungal Infections More Than Tumor Necrosis Factor-Alpha Inhibitors in Patients With Inflammatory Bowel Disease.</name><description>&lt;h4>Background&lt;/h4>Invasive fungal infections are a devastating complication of inflammatory bowel disease (IBD) treatment. We aimed to determine the incidence of fungal infections in IBD patients and examine the risk with tumor necrosis factor-alpha inhibitors (anti-TNF) compared with corticosteroids.&lt;h4>Methods&lt;/h4>In a retrospective cohort study using the IBM MarketScan Commercial Database we identified US patients with IBD and at least 6 months enrollment from 2006 to 2018. The primary outcome was a composite of invasive fungal infections, identified by ICD-9/10-CM codes plus antifungal treatment. Tuberculosis (TB) infections were a secondary outcome, with infections presented as cases/100 000 person-years (PY). A proportional hazards model was used to determine the association of IBD </description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Apr</publication><modification>2025-04-04T18:49:08.788Z</modification><creation>2025-04-04T18:49:08.788Z</creation></dates><accession>S-EPMC9999356</accession><cross_references><pubmed>36911593</pubmed><doi>10.1093/crocol/otad010</doi></cross_references></HashMap>